Second Genome

Second Genome applies microbiome analytics to drug discovery for multiple diseases. It partners with pharma on therapeutic programs rather than providing clinical FMT. Compared with OpenBiome it focuses on computational platforms and commercial partnerships without open patient treatment or grant distribution activities.